Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure Builds In Ventricular Assist Market

Executive Summary

With only two companies, Thoratec and HeartWare International, selling LVADs in the US, clinical data along with sales and product pipeline strategies have become paramount for capturing market share – and expanding the market to treat a wide range of class III heart failure patients.

Advertisement

Related Content

Thoratec Looks To Next-Generation LVADs To Revive Sinking Sales
Tug Of War In The LVAD Market
CMS Fields Many Suggestions And Criticisms On Proposed VAD Policy
Heart Failure Start-Ups Balance High-Risk, High-Reward Opportunity
Thoratec Takes Over Development Of Terumo’s DuraHeart II VAD
Reversing The Downward Spiral Of Heart Failure
Two Small Companies See Huge Opportunities In Heart Failure Device Space
Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth
Heart Failure Devices: Raising Roadblocks To Readmission
Market & Industry Briefs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT035599

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel